For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250605:nRSE5054La&default-theme=true
RNS Number : 5054L Optima Health PLC 05 June 2025
Optima Health plc
("Optima", the "Company", and, together with its subsidiaries, the "Group")
Notice of Full Year Results
LONDON, UK, 5 June 2025, Optima Health (AIM: OPT), the UK's leading provider
of technology enabled corporate health and wellbeing solutions, will announce
its announce its unaudited results for the full year ended 31 March 2025 on
Tuesday 8 July 2025.
Jonathan Thomas, Chief Executive Officer and Heidi Giles, Chief Financial
Officer, will host an in-person analyst briefing at 11:00am BST on the day of
the results at 85 Gresham Street, London, EC2V 7NQ. There will also be a live
webcast and conference call with a Q&A session.
For more details or to attend the briefing, please contact
optimahealth@icrinc.com
Enquiries
Optima Health +44(0)3300085113
Jonathan Thomas, CEO media@OptimaHealth.co.uk
Heidi Giles, CFO
Nominated Adviser and Corporate Broker
Panmure Liberum Limited +44 (0)20 3100 2000
Emma Earl / Will Goode/ Mark Rogers
Rupert Dearden
UK Financial PR Adviser optimahealth@icrinc.com
ICR Healthcare
Mary-Jane Elliott / Angela Gray / Lindsey Neville
About Optima Health
Optima Health is the UK's leading provider of occupational health and
wellbeing services, directly influencing and improving people's lives for 25
years. Optima Health's incredible team of professionals quickly and
effectively encapsulate client's needs, supporting organisations of all shapes
and sizes. Through tailored solutions and innovative systems, Optima Health
offers unparalleled clinical expertise to its clients. These solutions ensure
that processes are simple and allow its clients to spend more time focusing on
their employees driving a healthy, high-performing workplace. For more
information visit www.optima health.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NORFLFLTRRISIIE